Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-042453

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Christopher Bowden
Officer — Chief Medical Officer
Period of report
Jul 10, 2018
Accepted (ET)
Jul 12, 2018 · 4:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockF2Jul 10, 2018M2,000$35.16A2,924D
Common stockF4Jul 10, 2018S1,200$86.42D1,724D
Common stockF5Jul 10, 2018S800$87.26D924D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F6$35.16Jul 10, 2018M2,000D—May 30, 2024Common stock2,00093,000D

Explanation of responses